You just read:

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease

News provided by

Jazz Pharmaceuticals plc

Feb 08, 2017, 16:05 ET